Increased access to transplantation of highly sensitized patients under the new kidney allocation system. A single center experience

Hum Immunol. 2017 Mar;78(3):257-262. doi: 10.1016/j.humimm.2016.12.003. Epub 2016 Dec 9.

Abstract

We aimed to investigate the impact of the new kidney allocation system (KAS) on the rate of transplantation of sensitized patients at our center. Pre-KAS and post-KAS intervals were Jan 1st to Dec 3rd 2014 and Jan 1st 2015 to Dec 3rd 2015, respectively. The number of deceased-donor crossmatches performed by flow cytometry increased from 715 pre-KAS to 1188 post-KAS. The percent of crossmatches performed for sensitized patients with calculated panel reactive antibody (cPRA)>0% increased from 19% pre-KAS to 26% post-KAS (p<0.0001). The number of deceased-donor kidney transplants performed at our center increased from 115 pre-KAS to 125 post-KAS (9% increase). There was a significant increase in the percentage of deceased-donor kidney transplants received by sensitized candidates (from 14% to 26% pre- and post-KAS, respectively; p<0.0001). The highest increase was seen in the patients with cPRA>98%, from 0% to 9%, followed by the group with cPRA 50-79%, from 5% to 8%. This increase was balanced by a decrease of 12% in the percentage of non-sensitized recipients, and a modest decrease of 1% in the group with cPRA 1-49%. In conclusion, transplant rate has increased in sensitized patients after KAS. The highest increase was observed among highly sensitized patients (cPRA>98%).

Keywords: HLA sensitization; Kidney allocation system; Kidney transplantation; Panel reactive antibody.

MeSH terms

  • Adult
  • Aged
  • Female
  • Graft Survival
  • HLA Antigens / genetics
  • HLA Antigens / immunology
  • Histocompatibility Testing / methods
  • Humans
  • Isoantibodies / immunology
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Time Factors
  • Tissue Donors / statistics & numerical data*
  • Tissue and Organ Procurement / methods
  • Tissue and Organ Procurement / statistics & numerical data*
  • Transplant Recipients / statistics & numerical data*
  • Treatment Outcome
  • Young Adult

Substances

  • HLA Antigens
  • Isoantibodies